Cure My Disease

Don't miss your cure!

 Log in / Sign up

New digital platform aims to break the silence around hereditary cancer in families

NCT ID NCT04214210

Knowledge-focused Sponsor: University of Basel Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a digital health platform to help people with a hereditary risk of breast and ovarian cancer share their genetic test results with family members. Researchers worked with 128 participants in Switzerland and Korea to see if the tool reduced distress and improved communication. The goal was to make it easier for relatives to learn about their own cancer risk and get tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

128 people

The number who actually took part.

Started

Apr 2022

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Speak and read German, French, Italian, English, or Korean * Residence in Switzerland or in Korea * Has been identified with a pathogenic variant associated with HBOC or * Has ≥1 first-, second-degree relative or first cousing with HBOC * Mentally able to provide informed consent Exclusion Criteria: * mutation carriers who do not have any family members; * husbands and partners, although they may play an important role in decisions for genetic testing and risk management of disease, will not be included in the study; * participants with a prior diagnosis of a mental disease and those unable to provide informed consent; * those physically ill and not being able to complete a baseline survey; * those without access to the web through a computer, tablet, or smartphone.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hereditary breast ovarian cancer syndrome hereditary neoplastic syndrome ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Hereditary cancer Ovarian cancer

Contacts and locations

Locations

  • HFR Fribourg - Hôpital cantonal

    Fribourg, Canton of Fribourg, 1752, Switzerland

  • Hirslanden Clinic Des Grangettes

    Geneva, Canton of Geneva, 1224, Switzerland

  • Hopital du Jura - Service d' Oncology

    Delémont, Canton of Jura, 2800, Switzerland

  • Istituto Oncologico della Zvizzera Italiana

    Bellinzona, 6962, Switzerland

  • Kantonalspital Winterthur

    Winterthur, Canton of Zurich, 8401, Switzerland

  • Unite d'Oncogenetique et de Prevention des Cancers

    Geneva, 1205, Switzerland

  • Universitatklinik fur Medizinische Onkologie, Inselspital

    Bern, 3010, Switzerland

  • University Hospital Basel

    Basel, 4056, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.